253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC)
Publication
, Conference
Burnette, S; Poehlein, E; Lee, H-J; Force, J; Westbrook, K; Moore, H
Published in: Annals of Oncology
September 2021
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S470 / S470
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Burnette, S., Poehlein, E., Lee, H.-J., Force, J., Westbrook, K., & Moore, H. (2021). 253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC). In Annals of Oncology (Vol. 32, pp. S470–S470). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.536
Burnette, S., E. Poehlein, H. -. J. Lee, J. Force, K. Westbrook, and H. Moore. “253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC).” In Annals of Oncology, 32:S470–S470. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.536.
Burnette S, Poehlein E, Lee H-J, Force J, Westbrook K, Moore H. 253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC). In: Annals of Oncology. Elsevier BV; 2021. p. S470–S470.
Burnette, S., et al. “253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC).” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S470–S470. Crossref, doi:10.1016/j.annonc.2021.08.536.
Burnette S, Poehlein E, Lee H-J, Force J, Westbrook K, Moore H. 253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC). Annals of Oncology. Elsevier BV; 2021. p. S470–S470.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S470 / S470
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis